Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2024-2032

Chronic Obstructive Pulmonary Disease (COPD) Market Outlook

The chronic obstructive pulmonary disease (COPD) market size was valued at USD 18.4 billion in 2023, driven by the increased tobacco consumption  across the 7 major markets. The market is expected to grow at a CAGR of 5.3% during the forecast period of 2024-2032, with the values likely to rise from USD 19.4 billion in 2024 to USD 29.4 billion by 2032.

Chronic Obstructive Pulmonary Disease (COPD): Introduction

Chronic obstructive pulmonary disease (COPD) is a common lung disease in which a patient suffers from breathing issues because the airflow gets restricted. It is also known as emphysema or chronic bronchitis. There are chances that lungs may get clogged with phlegm in people suffering from it. The symptoms of chronic obstructive pulmonary disease include cough (with or without phlegm), breathing issues, wheezing, and exhaustion. The most common causes of chronic obstructive pulmonary disease include smoking and air pollution.

Chronic Obstructive Pulmonary Disease (COPD) Market Analysis

The increasing prevalence of chronic obstructive pulmonary disease within the 7 major markets is directly contributing to the chronic obstructive pulmonary disease market demand. The increase in COPD prevalence is due to several factors such as increasing aging population, increased urbanization, and other lifestyle habits. As people age, they are more susceptible to developing COPD due to decreased immunity rates with age. The increasing population of vehicles has been contributing to a rise in pollution levels in the urban cities and with the population density being high, it is directly contributing to the rise in COPD. Additionally, increased involvement of smoking and decreased health maintenance contributes to the rise in number of cases.

The chronic obstructive pulmonary disease market growth is driven by the advent of novel treatment alternatives for patients. In March 2023, Sanofi revealed that their potential COPD drug called Dupixent® showed favourable results in the Phase 3 trials. It is the first and only biologic to demonstrate a 30% reduction in acute as well as moderate exacerbations of COPD.

In addition to pharmacological treatments, surgical interventions like the lung volume reduction surgery, bullectomy and lung transplant are also being used on patients with severe conditions. With the prevalence of personalised treatments and targeted biologics, triple drug combinations that include the use of long-acting beta antagonists (LABAs), long-acting muscarinic antagonists (LAMA), and inhaled steroids are being considered as a valid treatment alternative. As research continues to progress, we can anticipate some significant treatment breakthroughs in the coming years, which will contribute significantly to the chronic obstructive pulmonary disease market share in the future.

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation

Market Breakup by Treatment Type

• Drugs
  • Bronchodilator Monotherapy
    • Short-Acting Beta-2 Agonists
    • Long-Acting Beta-2 Agonists
    • Others
  • Anti-Inflammatory Drugs
    • Oral and Inhaled Corticosteroids
    • Anti-Leukotrienes
  • Others

• Surgery
  • Lung Volume Reduction Surgery
  • Lung Transplant
  • Bullectomy
  • Others

• Oxygen Therapy

• Others

Market Breakup by Disease Type

• Emphysema

• Chronic Bronchitis

Market Breakup by Route of Administration

• Oral

• Inhalation

• Parenteral

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Chronic Obstructive Pulmonary Disease (COPD) Market Overview

The United States held a substantial portion of the chronic obstructive pulmonary disease market share during the historical period. Factors like a prominent healthcare ecosystem, coupled with core MedTech companies prevailing in the area contributed to the significant market growth. This trend is expected to continue, with the launch of several informative initiatives like the Learn More Breathe Better® Community Subcontract Program, which is organised by the National Heart, Lung, and Blood Institute (NHLBI). This program offers funding to organisations all over the country to offer better health education initiatives.

As a hub of medical inventions, Europe has been a key player in the COPD market. Having significant research and academic institutions along with a well-equipped infrastructure fosters major scope for the development of groundbreaking treatments.

The Asia Pacific region is home to various developing countries undergoing rapid urbanisation. As a result, the population living in the region is more susceptible to developing COPD due to higher exposure to pollution levels. Moreover, countries like Japan and China have a massive size of geriatric population, leaving the countries at an increased risk of facing more COPD cases. Identifying the current trend, the region is experiencing essential infrastructure developments in hospitals and research labs to combat the high chronic obstructive pulmonary disease market demand that may arise in the future.

Chronic Obstructive Pulmonary Disease (COPD) Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• GlaxoSmithKline plc (GSK)

• AstraZeneca

• Boehringer Ingelheim

• Novartis

• Teva Pharmaceutical Industries

• Viatris (formerly Mylan)

• Sunovion Pharmaceuticals

• Cipla

• Merck & Co., Inc.

• Vectura Group

• Pfizer Inc.

• Regeneron Pharmaceuticals

• Circassia Pharmaceuticals

• Theravance Biopharma

• Almirall

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report